Asciminib

Asciminib is a tyrosine kinase inhibitor (TKI) developed for the treatment of chronic myeloid leukemia (CML), specifically targeting the BCR-ABL1 kinase. It is designed to inhibit the growth and survival of leukemia cells by blocking the activity of the BCR-ABL1 protein, which is characteristic of CML.

Indications

Treatment of chronic phase chronic myeloid leukemia (CP-CML) in adult patients who are resistant or intolerant to prior therapy, including tyrosine kinase inhibitors.

Dosage

The recommended dosage of asciminib may vary based on individual patient factors and prior treatment history. Typically administered orally once daily.

Contra-Indications

Hypersensitivity to asciminib or any component of the formulation.

Special Precautions

-Monitor liver function tests regularly due to the potential risk of hepatotoxicity. -Asciminib may cause myelosuppression (reduction in blood cell counts); monitor blood counts periodically. -Use with caution in patients with pre-existing cardiovascular conditions or risk factors.

Side Effects

Common side effects may include: -Nausea -Diarrhea -Fatigue -Headache -Increased liver enzymes

Drug Interactions

Asciminib may interact with other medications, particularly those metabolized by or affecting CYP3A4 enzymes. Avoid concomitant use with strong CYP3A4 inhibitors or inducers.